Bionova opens Fremont process development and pilot plant

Biocon Academy conducts 9th Graduation Day

Notably, 36 female students have been placed in Production and Manufacturing roles, reflecting the growing representation of women in core biotech operations

Biocon launches GLP -1, Liraglutide, in UK

The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K.

India’s CRDMO sector growth potential at $22 - $25 Billion by 2035: BCG-IPSO Report

Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain

Equillium and Biocon announce positive data from Phase 2 study evaluating Itolizumab for ulcerative colitis

Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo

Hikal appoints Dr. Raghavendar Morthala as Head – CDMO R&T Pharma & Animal Health BU

Biocon’s S&P Global ESG Score improves to 69 for 2024

Biocon’s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53

Suven Life Sciences announces first subjects dosed in phase-1 clinical trial of SUVN-I6107

The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs

Sentynl Therapeutics receives USFDA acceptance and priority review of new drug application for CUTX-101 product candidate for treatment of Menkes disease

Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A

Innovent receives NMPA approval for Taletrectinib Adipate capsule from NMPA

DOVBLERON marks the 13th addition to Innovent’s commercial portfolio